Purecodon (hong Kong) Biopharma Ltd.

Zonghao Qiu

Zhenhua Sun

Chijian Zuo

Qiangbo Hou

Yang Zhao

The present disclosure relates to a recombinant nucleic acid molecule and an application thereof in preparation of a circular RNA, and in particular, to a recombinant nucleic acid molecule for preparing a circular RNA, a recombinant expression vector, a circular RNA, a composition, a method for preparing a circular RNA, a method for expressing a target polypeptide in a cell, a method for screening a target coding region sequence, a system for screening a target coding region sequence, and a method for screening a ribozyme recognition site sequence. The recombinant nucleic acid molecule provided by the present disclosure provides a Clean PIE system with a novel structure for preparing a circRNA in vitro, which can avoid introducing additional exon sequences into the circular RNA, improve the sequence accuracy of circular RNA molecules, reduce changes in a secondary structure of the circular RNA, and further reduce the immunogenicity of the circular RNA, and has a good application prospects in the fields of nucleic acid vaccines, expression of therapeutic proteins, gene therapy, and the like.

Recombinant nucleic acid molecule and application thereof in preparation of circular RNA

The present disclosure relates to a recombinant nucleic acid molecule based on point mutation of translation initiation element and use thereof in the preparation of circular RNA, and in particular to a recombinant nucleic acid molecule for preparing circular RNA, a recombinant expression vector, circular RNA, a composition, a method for preparing circular RNA, a method for expressing a target polypeptide in a cell, a method for preventing or treating a disease, a method for editing a translation initiation element sequence, and a system for editing a translation initiation element sequence. The recombinant nucleic acid molecule provided by the present disclosure provides a novel Clean PIE system for the in vitro preparation of circular RNA, which can avoid introducing additional exon sequences into circular RNA, improve sequence accuracy of circular RNA molecules, reduce changes in a secondary structure of circular RNA, and then reduce immunogenicity of circular RNA, and has a good application prospect in the fields of nucleic acid vaccines, expression of therapeutic proteins, gene therapy, etc.

Growing community of inventors

Suzhou, China

Zonghao Qiu